Solana Mobile has enhanced its Seeker Dashboard by partnering with Webcade, a retro arcade game on the Solana dApp Store. Verified Seeker holders can now claim exclusive badges, unlock bonus plays, and compete on a dedicated leaderboard, adding value beyond just owning the hardware. This partnership integrates with the Seeker ecosystem, which includes over 150,000 shipped devices and a growing dApp Store with 1,000+ applications. The collaboration benefits Webcade with increased distribution and gives Seeker owners free in-game advantages, reinforcing the commercial appeal of Solana Mobile's hardware and software ecosystem.
Solana Mobile updates its Seeker Dashboard with new Webcade perks. For readers following the broader crypto market, here is Pluang's snapshot as of Sep 22, 2026 00:52 WIB: 40 of 50 major cryptocurrencies rose today. Notable movers include XLM at Rp3.690 with a 6.31% increase, BTC at Rp1.524.504.152 up 5.62%, and ADA at Rp4.282 rising 5.49%.
Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to...
Fannie Mae completed its 28th sale of non-performing loans, selling 919 loans totaling $203.3 million in unpaid principal to Residential Credit Opportunities Trust IX-D. The loans have an average size of $221,222 and a weighted average interest rate ...
Sergey Nazarov, co-founder of Chainlink, will speak at Sibos 2026, a major financial conference, across three sessions covering tokenized assets, intelligent money, and interoperable finance. The event, held from September 28 to October 1 in Miami Be...
SanDisk shares fell 2% while the broader memory sector, including peers Micron and Western Digital, saw gains of 3% and 0.8% respectively. This divergence occurred without any company-specific news, suggesting profit-taking or position trimming after...
A class action lawsuit has been filed against Ardelyx, Inc. for allegedly misleading investors about the commercial performance and growth prospects of its key drugs, IBSRELA and XPHOZAH, between January 2025 and August 2026. The lawsuit claims Ardel...
